<DOC>
	<DOCNO>NCT01744925</DOCNO>
	<brief_summary>This study design evaluate safety efficacy icotinib routine dose high dose second-line treatment non-small cell lung cancer patient epidermal growth factor receptor wild type .</brief_summary>
	<brief_title>Icotinib Different Doses Second-line Treatment Non-small Cell Lung Cancer Patients With Wild Type EGFR</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Recurrent progressive NonSmall Cell Lung Cancer stage IV IIIB patient Histologic cytologic confirmation . Wild type epidermal growth factor receptor status . Progressed firstline chemotherapy . No previous systemic anticancer therapy . Measurable lesion accord response evaluation criterion solid tumor least one measurable lesion previously irradiate . Provision write informed consent . Evidence clinically active Interstitial Lung Diseases ( Patients chronic , stable , radiographic change asymptomatic need exclude ) . Positive epidermal growth factor receptor mutation . Known severe hypersensitivity icotinib excipients product . Evidence significant clinical disorder laboratory find make undesirable subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>